2 Reasons Investors Should Buy Chewy Stock

Chewy reported fiscal 2025 net sales of $12.6 billion, up 6% year over year, with operating income surging 125% and free cash flow rising 24% to $562 million. The article argues the stock looks increasingly attractive after a near 80% drop from its all-time high, citing a forward P/E of 16 versus a trailing P/E of 50 and analyst expectations for 9% sales growth and 28% net income growth next year. The tone is constructive but mainly valuation-driven rather than a near-term catalyst for the broader market.

Analysis

The market is still treating CHWY like a low-quality cyclical, but the more important shift is that the business is becoming structurally less elastic to the macro cycle. Once a pet retailer crosses into recurring pharmacy, telehealth, and clinic economics, the revenue mix changes from pure discretionary replenishment to something closer to a quasi-healthcare subscription stream, which should compress volatility in both demand and gross margin over time. That matters because the equity no longer needs heroic top-line growth to rerate; it only needs proof that higher-margin services are scaling faster than fulfillment costs.

The key second-order effect is competitive: Amazon can pressure assortment and price, but it is much harder for a generalist to replicate the care pathway, prescriptions, and vet-clinic ecosystem without materially worse unit economics. That creates a moat that is not obvious in headline retail comps, and it also raises switching costs as customer data and pet histories accumulate inside the platform. If clinic rollout and pharma attach rates keep rising, the market will likely start valuing CHWY on recurring revenue and customer lifetime value rather than on near-term retail margins.

The setup is still fragile near term because the stock can be punished if management does not show acceleration in the next couple of quarters. The biggest risk is that the market has already partially discounted the turnaround, so any deceleration in active customer growth, pharmacy penetration, or clinic economics could knock the multiple back down before the fundamental thesis is fully recognized. On the other hand, if the next print confirms operating leverage without a spike in fulfillment spend, this can rerate quickly over the next 3-6 months rather than waiting for annual results.

The contrarian angle is that consensus is likely overfocusing on the absolute P/E and underweighting the mix shift in earnings quality. A low-teens forward multiple is not expensive if the earnings base is moving toward recurring, higher-margin services and free cash flow is compounding faster than reported net income suggests. The market may be missing that CHWY’s real optionality is not in pet food share gains, but in monetizing an owned customer relationship across multiple care layers.

Key Decisions for Investors

• Go long CHWY on a 3-6 month horizon ahead of the next two earnings prints; prefer adding on pullbacks rather than chasing strength. Risk/reward improves if the stock stays below a mid-teens forward multiple while FCF continues to compound.
• Use a call spread in CHWY for upside exposure into the next 1-2 quarters; target a rerating on evidence of mix shift and operating leverage. Limit downside to premium paid if clinic/pharmacy rollout proves slower than expected.
• Pair long CHWY / short a basket of generalist discretionary retailers over 1-2 quarters to isolate the pet-healthcare mix premium. The thesis is that CHWY’s revenue quality should decouple from pure retail demand sensitivity.
• Avoid shorting on valuation alone; the cleaner bearish trigger would be deterioration in active customer retention or gross margin compression over two consecutive quarters. Without that, the stock can stay disconnected from trailing multiples for longer than expected.
• If management commentary confirms accelerating services attach rates, add through year-end and look for a multi-quarter rerating rather than a quick trade. The upside case is driven by durability of earnings, not just multiple expansion.